Elevating Innovative Research
Research at TRF
TRF mission is to fund and support innovative research. At this stage we do not directly conduct research investigations.
TRF mission is to fund and support innovative research. At this stage we do not directly conduct research investigations.
Wendy’s background
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris vel augue vel lacus finibus tempor. Phasellus volutpat convallis neque eget accumsan. In eleifend odio venenatis ornare sodales. Curabitur in elementum dui. Mauris at neque ac nibh feugiat dictum. Sed consequat laoreet pharetra. Pellentesque eget quam porttitor, mattis mauris quis, efficitur nisl. Proin at nibh sodales, ultricies lectus quis, mattis neque. Quisque hendrerit malesuada dapibus. Maecenas volutpat nisl est, tincidunt malesuada leo ultrices ac. Pellentesque non nibh justo. Mauris porttitor sapien faucibus magna iaculis tempor. Phasellus vel fermentum odio. Nam sed mollis ligula. Morbi et turpis mauris.
Ut eleifend luctus nunc quis egestas. Cras a libero in ante gravida faucibus. Vestibulum in cursus est, non scelerisque nisl. Maecenas cursus laoreet porttitor. Praesent egestas non augue eget sodales. Nam consequat libero vel lorem tristique imperdiet. Proin laoreet dui nec neque sollicitudin, quis tristique lectus elementum. Praesent sodales egestas iaculis. Etiam sem arcu, commodo a elit ac, vestibulum pulvinar enim. Proin metus nunc, tristique vitae interdum vel, viverra vitae quam. Sed bibendum vestibulum posuere. Phasellus convallis enim eu libero vulputate, vitae tristique leo tincidunt. Sed sed magna dignissim, hendrerit mi ut, sodales dui. Aenean purus est, pretium ac consequat eu, tincidunt id velit. Fusce ultrices sit amet felis nec ullamcorper. Nullam id arcu tempor, porta dui sed, porttitor turpis.
Bessel van der Kolk, MD was a Principal Investigator for a Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored phase 3 program evaluating the efficacy of MDMA-Assisted Psychotherapy for the Treatment of Moderate to Severe Posttraumatic Stress Disorder (PTSD). This multi-center study was designed to provide information on whether the drug MDMA combined with psychotherapy is safe and helpful for people with PTSD. The Phase 3 clinical trials in the US, Canada, and Israel MDMA-assisted psychotherapy for PTSD was concluded in 2023.
MDMA-assisted psychotherapy for PTSD is currently in Phase 3 clinical trials in the US, Canada, and Israel. This means that previous studies have been completed that suggested MDMA-assisted psychotherapy is safe and effective for treating PTSD. The Phase 3 clinical trials will enroll more participants to determine if the previous study results were correct and collect more data on the risks and benefits of the drug.
On August 16, 2017, the FDA granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. The FDA grants this designation for treatments that (1) are intended alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition; and (2) preliminary clinical evidence indicates may demonstrate substantial improvement over existing therapies.
Morbi sodales sagittis enim non vestibulum. Mauris lobortis mi non efficitur vestibulum. Duis ullamcorper pulvinar lectus, eu consectetur nisl dapibus sed. Phasellus at bibendum leo.
Aliquam et ornare nunc, ac ultrices ex. Curabitur id enim eget tortor aliquet sollicitudin. Proin enim massa, maximus eget dui id, fermentum posuere ligula. Suspendisse sit amet sapien eget sapien molestie ultrices id vel ante. Mauris elementum ipsum eget pretium venenatis. Cras lacus enim, sodales eget risus sed, ullamcorper laoreet sapien. Curabitur at ipsum vitae mauris ultrices convallis ac rhoncus orci.
A gift to Trauma Research Foundation helps expand the field of trauma treatment by increasing awareness and providing access.
Please note we do not have a telephone number. To contact us please use the form on our general inquiry page